Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, today announced that the company will present Phase 1 data on ALLN-177, its lead product for the treatment of hyperoxaluria, at the American Society of Nephrology (ASN) Kidney Week 2014, being held November 11-16, 2014 at the Pennsylvania Convention Center in Philadelphia.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
